Hematopoietic Stem Cell Transplant in Korea: Process and Timeline (2026)

Hematopoietic stem cell transplantation clears diseased bone marrow with high-dose chemotherapy, then reintroduces healthy stem cells through an IV line so the body can start making blood again. As of 2026, patients typically plan for a total stay of 6-8 weeks, including 3-6 weeks of hospitalization, and allogeneic transplants can run longer than that.

Key Takeaways

• Hematopoietic stem cell transplantation is a treatment in which high-dose chemotherapy clears out diseased bone marrow and healthy stem cells are then introduced to restart blood production; the transplant itself is not a surgery but closer to an IV infusion.
• Engraftment - when the new cells settle in and begin producing blood - usually takes 2-4 weeks, and because infection risk is high during this window, patients stay in a sterile isolation room.
• As of 2026, the typical total stay is 6-8 weeks, including 3-6 weeks of hospitalization. For allogeneic transplants, close monitoring often continues for around 100 days post-transplant to manage graft-versus-host disease and infection risk.
• Autologous transplants use the patient's own cells, while allogeneic transplants use a donor's cells (sibling, haploidentical, unrelated donor, or cord blood, in that order of preference). Allogeneic transplant is more common for acute leukemia, while autologous transplant is more typical for multiple myeloma and relapsed lymphoma.
• The remote review (pre-arrival review) fee is KRW 1,000,000 (about US$730), and this amount is deducted from the treatment cost if the patient proceeds with treatment (based on National Cancer Center Korea, NCCN patient guidelines, and Medical Korea).

What Is Hematopoietic Stem Cell Transplantation and Why Is It Needed?

• Hematopoietic stem cells are the source cells that give rise to red blood cells, white blood cells, and platelets, and many blood cancers originate in the bone marrow. Chemotherapy strong enough to clear the marrow eliminates the cancer cells, but it also destroys the marrow's ability to make blood - so healthy stem cells are introduced afterward to rebuild it.
• In an autologous transplant, the patient's own stem cells are collected and frozen while the disease is under control, then reinfused after high-dose chemotherapy. There is no rejection risk, but there is a chance that cancer cells may be collected along with the healthy cells.
• In an allogeneic transplant, donor cells are used, which can produce a graft-versus-cancer effect against any remaining cancer cells. However, the same immune activity can attack the patient's skin, gut, and liver, causing graft-versus-host disease (GVHD), which requires more careful management.

When Is Transplant Considered?

• Transplant is considered for acute leukemia patients who have achieved remission with chemotherapy but are judged to be at high risk of relapse, for lymphoma that has relapsed or failed to respond to standard treatment, in the course of treating multiple myeloma, and for some cases of myelodysplastic syndrome. Autologous transplant is more common for multiple myeloma and relapsed lymphoma, while allogeneic transplant is more common for acute leukemia.
• Eligibility for transplant depends not only on the disease itself but also on age, overall condition, and heart, lung, liver, and kidney function. If there is an active infection or organ function is compromised, the conditioning regimen may be hard to tolerate, so timing may be delayed or a reduced-intensity approach considered.
• Allogeneic transplant requires a donor, and the search typically proceeds in this order: siblings, haploidentical donors (parent or child), unrelated donors, then cord blood. Even without a fully matched donor, alternatives such as haploidentical transplant, unrelated donor searches, or cord blood remain available.

What Does the Actual Treatment Process and Timeline Look Like?

• Step 1: In the first 1-2 weeks after arrival, staging tests, heart/lung/liver/kidney function tests, and infection screening are performed. For allogeneic transplant, donor tissue-matching and health screening are conducted in parallel. A central venous catheter is placed for chemotherapy and transfusions.
• Step 2: Conditioning chemotherapy is given over roughly 1 week.
• Step 3: On the scheduled day, the stem cells are infused intravenously. The infusion itself takes only a few tens of minutes.
• Step 4: Patients spend 2-4 weeks in a sterile isolation room until engraftment is confirmed. During this period, fever, mouth sores, and low blood counts are common, managed with transfusions and antibiotics.
• Step 5: Once engraftment is confirmed and the patient's condition stabilizes, they are discharged - but do not return home immediately. Instead, they stay within walking distance of the hospital for frequent outpatient visits. A typical pattern is 3-6 weeks of hospitalization within a 6-8 week total stay, and allogeneic transplant cases are often planned around monitoring through roughly 100 days post-transplant.

What About Side Effects and Recovery?

• During conditioning, nausea, mouth sores, diarrhea, hair loss, and severe fatigue are common. During the period of low blood counts, infection and bleeding are the greatest risks, so even a slight fever prompts immediate action.
• In allogeneic transplant, graft-versus-host disease can appear as skin rash, diarrhea, elevated liver enzymes, and dryness of the eyes and mouth - sometimes appearing acutely early on, and sometimes developing into a chronic form months later. While immunosuppressants are being used, regular monitoring for viral reactivation is performed.
• It can take several months for strength and immunity to return, so many patients need to restart their vaccination schedule from the beginning. Long-term follow-up is also needed for reproductive function, thyroid health, bone health, and secondary cancers. Before returning home, a handoff summary and a three-way video consultation are arranged so that a local hematology team can take over care.

FAQ - If No Donor Can Be Found, Does That Mean Transplant Is Not Possible?

No. Even without a fully matched sibling, alternatives exist, including haploidentical transplant from a parent or child, searching for an unrelated donor, and cord blood. Korea has accumulated substantial experience with haploidentical transplants in particular. Which path is feasible depends on the type of disease, the patient's age, and urgency, and this can be assessed at the remote review (pre-arrival review) stage.

FAQ - Where Do Accompanying Family Members Stay, and When Can They Return Home?

Accompanying family members typically stay in a residence within walking distance of the hospital. Because sterile isolation wards have strict rules on visitor numbers and visiting hours, an interpreter explains these in detail. Return timing is often set at 2-3 weeks after discharge for autologous transplant, or around 100 days post-transplant for allogeneic transplant, but the final decision rests with the treating medical team. If the stay extends longer, a long-term treatment visa (G-1-10) can be arranged to allow the accompanying family member to remain in Korea.

Sources and Notes

• This article was written based on information regarding hematopoietic stem cell transplantation, blood cancers, medical visas, and treatment journey notes (based on National Cancer Center Korea, NCCN patient guidelines, Medical Korea, and HiKorea).
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on the individual's condition. Accurate diagnosis and treatment should always be determined through consultation with a medical professional.